EXECUTIVE ENGAGEMENTS
POOL
703
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
141
Interactions with Platform & by Email
PARTICIPANTS
28
Unique # Participated
VALIDATIONS
11
Responses Validated*
COMPANIES
34
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
22
PAGES
89
EDITION
5
PRICE
USD 5600
CODE
MCP22021
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
Amid the COVID-19 crisis, the global market for In Vivo Contract Research Organization (CRO) estimated at US$3.5 Billion in the year 2020, is projected to reach a revised size of US$5.7 Billion by 2027, growing at aCAGR of 7.1% over the period 2020-2027. Rodend-based, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$5.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Rodend based segment is readjusted to a revised 5.1% CAGR for the next 7-year period.
The In Vivo Contract Research Organization (CRO) market in the U.S. is estimated at US$1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$991.1 Million by the year 2027 trailing a CAGR of 6.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.7% and 5.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.
SELECT PLAYERS
American Preclinical Services, LLC.; Charles River Laboratories; Covance Inc.; Evotec (US), Inc.; ICON Plc; inVentiv Health; Parexel International; Pharmaceutical Product Development, LLC (PPD); Quintiles; Theorem Clinical research; WuXi AppTec, Inc.
SEGMENTS
» Product Type (Rodend-based, Non-Rodend based) » Toxicology (GLP, Non-GLP) » Indication (Oncology, Autoimmune / Inflammatory Conditions, Pain Management, Other Indications)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| World Market Trajectories |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for In Vivo Contract Research Organization (CRO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Rodend-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Rodend-based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Rodend-based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Non-Rodend based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Non-Rodend based by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Non-Rodend based by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for GLP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Non-GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Non-GLP by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Non-GLP by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Autoimmune / Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Autoimmune / Inflammatory Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Autoimmune / Inflammatory Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Pain Management by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Pain Management by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| World Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| USA Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| USA 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Canada Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Canada 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Japan Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Japan 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| China Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| China 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe Historic Review for In Vivo Contract Research Organization (CRO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| France Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| France 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Germany Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Germany 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Italy Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Italy 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| UK Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| UK 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Rest of Europe Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of Europe 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Asia-Pacific 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Product Type - Rodend-based and Non-Rodend based Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Product Type - Percentage Breakdown of Value Sales for Rodend-based and Non-Rodend based for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Toxicology - GLP and Non-GLP Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Toxicology - Percentage Breakdown of Value Sales for GLP and Non-GLP for the Years 2012, 2020 & 2027 |
| Rest of World Current & Future Analysis for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World Historic Review for In Vivo Contract Research Organization (CRO) by Indication - Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
| Rest of World 15-Year Perspective for In Vivo Contract Research Organization (CRO) by Indication - Percentage Breakdown of Value Sales for Oncology, Autoimmune / Inflammatory Conditions, Pain Management and Other Indications for the Years 2012, 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 34 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com